Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


Oliena Studio

Stroke and language recovery: 9000+ videos

EspañolItalianoSarduEnglish | PDF+


  Liver Diseases

  Free Subscription


Articles published in Gut

Retrieve available abstracts of 151 articles:
HTML format
Text format



Single Articles


    December 2019
  1. JOOSSENS M, Faust K, Gryp T, Nguyen ATL, et al
    Gut microbiota dynamics and uraemic toxins: one size does not fit all.
    Gut. 2019;68:2257-2260.
    PubMed     Text format    


    November 2019
  2. XU WP, Liu JP, Feng JF, Zhu CP, et al
    miR-541 potentiates the response of human hepatocellular carcinoma to sorafenib treatment by inhibiting autophagy.
    Gut. 2019 Nov 14. pii: gutjnl-2019-318830. doi: 10.1136/gutjnl-2019-318830.
    PubMed     Text format     Abstract available


  3. JOHN M, Kim KJ, Bae SDW, Qiao L, et al
    Role of BMP-9 in human liver disease.
    Gut. 2019;68:2097-2100.
    PubMed     Text format    


  4. GJORGJIEVA M, Sobolewski C, Dolicka D, Correia de Sousa M, et al
    miRNAs and NAFLD: from pathophysiology to therapy.
    Gut. 2019;68:2065-2079.
    PubMed     Text format     Abstract available


  5. WONG VW, Irles M, Wong GL, Shili S, et al
    Unified interpretation of liver stiffness measurement by M and XL probes in non-alcoholic fatty liver disease.
    Gut. 2019;68:2057-2064.
    PubMed     Text format     Abstract available


    October 2019
  6. LEE SW, Kwon JH, Lee HL, Yoo SH, et al
    Comparison of tenofovir and entecavir on the risk of hepatocellular carcinoma and mortality in treatment-naive patients with chronic hepatitis B in Korea: a large-scale, propensity score analysis.
    Gut. 2019 Oct 31. pii: gutjnl-2019-318947. doi: 10.1136/gutjnl-2019-318947.
    PubMed     Text format     Abstract available


  7. CHEN Y, Lin XY
    Are the 5-hydroxymethylcytosine-based wd-scores really superior over alpha-fetoprotein for the early diagnosis of hepatocellular carcinoma?
    Gut. 2019 Oct 25. pii: gutjnl-2019-319853. doi: 10.1136/gutjnl-2019-319853.
    PubMed     Text format    


  8. FOGLIA B, Parola M
    Of FACT complex and oxidative stress response: a KEAP1/NRF2-dependent novel mechanism sustaining hepatocellular carcinoma progression.
    Gut. 2019 Oct 15. pii: gutjnl-2019-319609. doi: 10.1136/gutjnl-2019-319609.
    PubMed     Text format    


  9. WANG D, Li X, Li J, Lu Y, et al
    APOBEC3B interaction with PRC2 modulates microenvironment to promote HCC progression.
    Gut. 2019;68:1846-1857.
    PubMed     Text format     Abstract available


  10. KORF H, du Plessis J, van Pelt J, De Groote S, et al
    Inhibition of glutamine synthetase in monocytes from patients with acute-on-chronic liver failure resuscitates their antibacterial and inflammatory capacity.
    Gut. 2019;68:1872-1883.
    PubMed     Text format     Abstract available


  11. CAUSSY C, Ajmera VH, Puri P, Hsu CL, et al
    Serum metabolites detect the presence of advanced fibrosis in derivation and validation cohorts of patients with non-alcoholic fatty liver disease.
    Gut. 2019;68:1884-1892.
    PubMed     Text format     Abstract available


    September 2019
  12. MARTI-RODRIGO A, Alegre F, Moragrega AB, Garcia-Garcia F, et al
    Rilpivirine attenuates liver fibrosis through selective STAT1-mediated apoptosis in hepatic stellate cells.
    Gut. 2019 Sep 17. pii: gutjnl-2019-318372. doi: 10.1136/gutjnl-2019-318372.
    PubMed     Text format     Abstract available


  13. WANG C, Wang H, Lieftink C, du Chatinier A, et al
    CDK12 inhibition mediates DNA damage and is synergistic with sorafenib treatment in hepatocellular carcinoma.
    Gut. 2019 Sep 13. pii: gutjnl-2019-318506. doi: 10.1136/gutjnl-2019-318506.
    PubMed     Text format     Abstract available


  14. CHANG Y, Ryu S, Sung KC, Cho YK, et al
    Alcoholic and non-alcoholic fatty liver disease and associations with coronary artery calcification: evidence from the Kangbuk Samsung Health Study.
    Gut. 2019;68:1667-1675.
    PubMed     Text format     Abstract available


    August 2019
  15. ARECHEDERRA M
    New warning signs on the road: 5-hydroxymethylcytosine-based liquid biopsy for the early detection of hepatocellular carcinoma.
    Gut. 2019 Aug 7. pii: gutjnl-2019-319339. doi: 10.1136/gutjnl-2019-319339.
    PubMed     Text format    


  16. SAROBE P, Corrales F
    Getting insights into hepatocellular carcinoma tumour heterogeneity by multiomics dissection.
    Gut. 2019 Aug 2. pii: gutjnl-2019-319410. doi: 10.1136/gutjnl-2019-319410.
    PubMed     Text format    


  17. HENDRIKX T, Duan Y, Wang Y, Oh JH, et al
    Bacteria engineered to produce IL-22 in intestine induce expression of REG3G to reduce ethanol-induced liver disease in mice.
    Gut. 2019;68:1504-1515.
    PubMed     Text format     Abstract available


    July 2019
  18. CAI J, Chen L, Zhang Z, Zhang X, et al
    Genome-wide mapping of 5-hydroxymethylcytosines in circulating cell-free DNA as a non-invasive approach for early detection of hepatocellular carcinoma.
    Gut. 2019 Jul 29. pii: gutjnl-2019-318882. doi: 10.1136/gutjnl-2019-318882.
    PubMed     Text format     Abstract available


  19. GUERRA MT, Florentino RM, Franca A, Lima Filho AC, et al
    Expression of the type 3 InsP3 receptor is a final common event in the development of hepatocellular carcinoma.
    Gut. 2019 Jul 17. pii: gutjnl-2018-317811. doi: 10.1136/gutjnl-2018-317811.
    PubMed     Text format     Abstract available


  20. KIM DH, Choi SH, Park SH, Kim KW, et al
    Meta-analysis of the accuracy of Liver Imaging Reporting and Data System category 4 or 5 for diagnosing hepatocellular carcinoma.
    Gut. 2019 Jul 12. pii: gutjnl-2019-318555. doi: 10.1136/gutjnl-2019-318555.
    PubMed     Text format    


  21. QUECK A, Carnevale R, Uschner FE, Schierwagen R, et al
    Role of portal venous platelet activation in patients with decompensated cirrhosis and TIPS.
    Gut. 2019 Jul 3. pii: gutjnl-2019-319044. doi: 10.1136/gutjnl-2019-319044.
    PubMed     Text format    


  22. MUSSO O, Beraza N
    Hepatocellular carcinomas: evolution to sorafenib resistance through hepatic leukaemia factor.
    Gut. 2019 Jul 3. pii: gutjnl-2019-318999. doi: 10.1136/gutjnl-2019-318999.
    PubMed     Text format    



  23. Correction: Opposite roles of cannabinoid receptors 1 and 2 in hepatocarcinogenesis.
    Gut. 2019;68:1342.
    PubMed     Text format    


  24. LONGERICH T, Endris V, Neumann O, Rempel E, et al
    RSPO2 gene rearrangement: a powerful driver of beta-catenin activation in liver tumours.
    Gut. 2019;68:1287-1296.
    PubMed     Text format     Abstract available


  25. BERRAONDO P, Martini PGV, Avila MA, Fontanellas A, et al
    Messenger RNA therapy for rare genetic metabolic diseases.
    Gut. 2019;68:1323-1330.
    PubMed     Text format     Abstract available


    June 2019
  26. GOUGELET A
    Epigenetic modulation of immunity: towards new therapeutic avenues in hepatocellular carcinoma?
    Gut. 2019 Jun 26. pii: gutjnl-2019-319084. doi: 10.1136/gutjnl-2019-319084.
    PubMed     Text format    


  27. ZHANG Q, Lou Y, Yang J, Wang J, et al
    Integrated multiomic analysis reveals comprehensive tumour heterogeneity and novel immunophenotypic classification in hepatocellular carcinomas.
    Gut. 2019 Jun 21. pii: gutjnl-2019-318912. doi: 10.1136/gutjnl-2019-318912.
    PubMed     Text format     Abstract available


  28. TAO L, Ma W, Wu L, Xu M, et al
    Glial cell line-derived neurotrophic factor (GDNF) mediates hepatic stellate cell activation via ALK5/Smad signalling.
    Gut. 2019 Jun 6. pii: gutjnl-2018-317872. doi: 10.1136/gutjnl-2018-317872.
    PubMed     Text format     Abstract available


  29. MITCHELL J, O'Beirne J
    Benefit of haemostatic spray in variceal bleeding: early application of spray or early application of guidelines?
    Gut. 2019;68:1134-1135.
    PubMed     Text format    


  30. HYUN J, Oh SH, Premont RT, Guy CD, et al
    Dysregulated activation of fetal liver programme in acute liver failure.
    Gut. 2019;68:1076-1087.
    PubMed     Text format     Abstract available


  31. PINYOL R, Montal R, Bassaganyas L, Sia D, et al
    Molecular predictors of prevention of recurrence in HCC with sorafenib as adjuvant treatment and prognostic factors in the phase 3 STORM trial.
    Gut. 2019;68:1065-1075.
    PubMed     Text format     Abstract available


  32. ALFERINK LJ, Kiefte-de Jong JC, Erler NS, Veldt BJ, et al
    Association of dietary macronutrient composition and non-alcoholic fatty liver disease in an ageing population: the Rotterdam Study.
    Gut. 2019;68:1088-1098.
    PubMed     Text format     Abstract available


    May 2019
  33. XIANG DM, Sun W, Zhou T, Zhang C, et al
    Oncofetal HLF transactivates c-Jun to promote hepatocellular carcinoma development and sorafenib resistance.
    Gut. 2019 May 22. pii: gutjnl-2018-317440. doi: 10.1136/gutjnl-2018-317440.
    PubMed     Text format     Abstract available


  34. DOHAN A, Gallix B, Guiu B, Le Malicot K, et al
    Early evaluation using a radiomic signature of unresectable hepatic metastases to predict outcome in patients with colorectal cancer treated with FOLFIRI and bevacizumab.
    Gut. 2019 May 17. pii: gutjnl-2018-316407. doi: 10.1136/gutjnl-2018-316407.
    PubMed     Text format     Abstract available


  35. KRENKEL O, Hundertmark J, Abdallah AT, Kohlhepp M, et al
    Myeloid cells in liver and bone marrow acquire a functionally distinct inflammatory phenotype during obesity-related steatohepatitis.
    Gut. 2019 May 10. pii: gutjnl-2019-318382. doi: 10.1136/gutjnl-2019-318382.
    PubMed     Text format     Abstract available


  36. LIU M, Zhou J, Liu X, Feng Y, et al
    Targeting monocyte-intrinsic enhancer reprogramming improves immunotherapy efficacy in hepatocellular carcinoma.
    Gut. 2019 May 10. pii: gutjnl-2018-317257. doi: 10.1136/gutjnl-2018-317257.
    PubMed     Text format     Abstract available


  37. RUIZ DE GALARRETA M, Lujambio A
    Hepatocellular carcinoma: killing one bird with two stones.
    Gut. 2019 May 10. pii: gutjnl-2019-318649. doi: 10.1136/gutjnl-2019-318649.
    PubMed     Text format    


  38. IBRAHIM M, El-Mikkawy A, Abdel Hamid M, Abdalla H, et al
    Early application of haemostatic powder added to standard management for oesophagogastric variceal bleeding: a randomised trial.
    Gut. 2019;68:844-853.
    PubMed     Text format     Abstract available


    April 2019
  39. SCOAZEC JY
    Hepatocellular adenomas: one step beyond.
    Gut. 2019 Apr 9. pii: gutjnl-2019-318299. doi: 10.1136/gutjnl-2019-318299.
    PubMed     Text format    


  40. CHE L, Chi W, Qiao Y, Zhang J, et al
    Cholesterol biosynthesis supports the growth of hepatocarcinoma lesions depleted of fatty acid synthase in mice and humans.
    Gut. 2019 Apr 6. pii: gutjnl-2018-317581. doi: 10.1136/gutjnl-2018-317581.
    PubMed     Text format     Abstract available


    March 2019
  41. ZHU Y, Yang J, Xu D, Gao XM, et al
    Disruption of tumour-associated macrophage trafficking by the osteopontin-induced colony-stimulating factor-1 signalling sensitises hepatocellular carcinoma to anti-PD-L1 blockade.
    Gut. 2019 Mar 22. pii: gutjnl-2019-318419. doi: 10.1136/gutjnl-2019-318419.
    PubMed     Text format     Abstract available


  42. CUBERO FJ, Martinez-Chantar ML
    Plasticity of adult hepatocytes and readjustment of cell fate: a novel dogma in liver disease.
    Gut. 2019 Mar 18. pii: gutjnl-2019-318218. doi: 10.1136/gutjnl-2019-318218.
    PubMed     Text format    


  43. DE TONI EN, Schlesinger-Raab A, Fuchs M, Schepp W, et al
    Age independent survival benefit for patients with hepatocellular carcinoma (HCC) without metastases at diagnosis: a population-based study.
    Gut. 2019 Mar 16. pii: gutjnl-2018-318193. doi: 10.1136/gutjnl-2018-318193.
    PubMed     Text format     Abstract available


  44. KASPER P, Goeser T, Nierhoff D
    Oesophageal and scaly skin lesions associated with chronic cholestatic liver disease.
    Gut. 2019 Mar 16. pii: gutjnl-2019-318502. doi: 10.1136/gutjnl-2019-318502.
    PubMed     Text format    


    February 2019
  45. MERLEN G, Kahale N, Ursic-Bedoya J, Bidault-Jourdainne V, et al
    TGR5-dependent hepatoprotection through the regulation of biliary epithelium barrier function.
    Gut. 2019 Feb 5. pii: gutjnl-2018-316975. doi: 10.1136/gutjnl-2018-316975.
    PubMed     Text format     Abstract available


  46. CHU H, Duan Y, Yang L, Schnabl B, et al
    Small metabolites, possible big changes: a microbiota-centered view of non-alcoholic fatty liver disease.
    Gut. 2019;68:359-370.
    PubMed     Text format     Abstract available


    January 2019
  47. YUAN L, Jiang J, Liu X, Zhang Y, et al
    HBV infection-induced liver cirrhosis development in dual-humanised mice with human bone mesenchymal stem cell transplantation.
    Gut. 2019 Jan 30. pii: gutjnl-2018-316091. doi: 10.1136/gutjnl-2018-316091.
    PubMed     Text format     Abstract available


    December 2018
  48. MANN J, Reeves HL, Feldstein AE
    Liquid biopsy for liver diseases.
    Gut. 2018;67:2204-2212.
    PubMed     Text format     Abstract available


  49. JAVARY J, Allain-Courtois N, Saucisse N, Costet P, et al
    Liver Reptin/RUVBL2 controls glucose and lipid metabolism with opposite actions on mTORC1 and mTORC2 signalling.
    Gut. 2018;67:2192-2203.
    PubMed     Text format     Abstract available


  50. LI M, Xu C, Shi J, Ding J, et al
    Fatty acids promote fatty liver disease via the dysregulation of 3-mercaptopyruvate sulfurtransferase/hydrogen sulfide pathway.
    Gut. 2018;67:2169-2180.
    PubMed     Text format     Abstract available


    November 2018
  51. GILL US, Pallett LJ, Thomas N, Burton AR, et al
    Fine needle aspirates comprehensively sample intrahepatic immunity.
    Gut. 2018 Nov 28. pii: gutjnl-2018-317071. doi: 10.1136/gutjnl-2018-317071.
    PubMed     Text format     Abstract available


  52. ALFERINK LJM, Kiefte-de Jong JC, Darwish Murad S
    Animal protein intake and hepatic steatosis in the elderly: authors' response.
    Gut. 2018 Nov 21. pii: gutjnl-2018-317843. doi: 10.1136/gutjnl-2018-317843.
    PubMed     Text format    


  53. LV Y, Zuo L, Zhu X, Zhao J, et al
    Identifying optimal candidates for early TIPS among patients with cirrhosis and acute variceal bleeding: a multicentre observational study.
    Gut. 2018 Nov 10. pii: gutjnl-2018-317057. doi: 10.1136/gutjnl-2018-317057.
    PubMed     Text format     Abstract available


  54. CHEN Q, Shu C, Laurence AD, Chen Y, et al
    Effect of Huaier granule on recurrence after curative resection of HCC: a multicentre, randomised clinical trial.
    Gut. 2018;67:2006-2016.
    PubMed     Text format     Abstract available


    October 2018
  55. TANG GY, Mann JP
    Animal protein intake and hepatic steatosis in the elderly.
    Gut. 2018 Oct 30. pii: gutjnl-2018-317709. doi: 10.1136/gutjnl-2018-317709.
    PubMed     Text format    


  56. ZHAO Y, Shuen TWH, Toh TB, Chan XY, et al
    Development of a new patient-derived xenograft humanised mouse model to study human-specific tumour microenvironment and immunotherapy.
    Gut. 2018;67:1845-1854.
    PubMed     Text format     Abstract available


  57. FERNANDEZ J, Acevedo J, Wiest R, Gustot T, et al
    Bacterial and fungal infections in acute-on-chronic liver failure: prevalence, characteristics and impact on prognosis.
    Gut. 2018;67:1870-1880.
    PubMed     Text format     Abstract available


    September 2018
  58. KREMER AE, Le Cleac'h A, Lemoinne S, Wolf K, et al
    Antipruritic effect of bezafibrate and serum autotaxin measures in patients with primary biliary cholangitis.
    Gut. 2018 Sep 18. pii: gutjnl-2018-317426. doi: 10.1136/gutjnl-2018-317426.
    PubMed     Text format    


  59. CANI PD
    Human gut microbiome: hopes, threats and promises.
    Gut. 2018;67:1716-1725.
    PubMed     Text format     Abstract available


    August 2018
  60. MONTAGNER A, Le Cam L, Guillou H
    beta-catenin oncogenic activation rewires fatty acid catabolism to fuel hepatocellular carcinoma.
    Gut. 2018 Aug 4. pii: gutjnl-2018-316557. doi: 10.1136/gutjnl-2018-316557.
    PubMed     Text format    


  61. ASPICHUETA P
    Lipid-rich environment: a key role promoting carcinogenesis in obesity-related non-alcoholic fatty liver disease.
    Gut. 2018;67:1376-1377.
    PubMed     Text format    


  62. FUJIWARA N, Nakagawa H, Enooku K, Kudo Y, et al
    CPT2 downregulation adapts HCC to lipid-rich environment and promotes carcinogenesis via acylcarnitine accumulation in obesity.
    Gut. 2018;67:1493-1504.
    PubMed     Text format     Abstract available


  63. STRNAD P, Buch S, Hamesch K, Fischer J, et al
    Heterozygous carriage of the alpha1-antitrypsin Pi*Z variant increases the risk to develop liver cirrhosis.
    Gut. 2018 Aug 1. pii: gutjnl-2018-316228. doi: 10.1136/gutjnl-2018-316228.
    PubMed     Text format     Abstract available


    July 2018
  64. REN Z, Li A, Jiang J, Zhou L, et al
    Gut microbiome analysis as a tool towards targeted non-invasive biomarkers for early hepatocellular carcinoma.
    Gut. 2018 Jul 25. pii: gutjnl-2017-315084. doi: 10.1136/gutjnl-2017-315084.
    PubMed     Text format     Abstract available


  65. LIM CJ, Lee YH, Pan L, Lai L, et al
    Multidimensional analyses reveal distinct immune microenvironment in hepatitis B virus-related hepatocellular carcinoma.
    Gut. 2018 Jul 3. pii: gutjnl-2018-316510. doi: 10.1136/gutjnl-2018-316510.
    PubMed     Text format     Abstract available


  66. ROTMAN Y, Sanyal AJ
    Pioglitazone for the treatment of NASH in patients with prediabetes or type 2 diabetes mellitus-authors' response.
    Gut. 2018;67:1372.
    PubMed     Text format    


  67. CUSI K
    Pioglitazone for the treatment of NASH in patients with prediabetes or type 2 diabetes mellitus.
    Gut. 2018;67:1371.
    PubMed     Text format    


    June 2018
  68. BERNSMEIER C, Triantafyllou E, Brenig R, Lebosse FJ, et al
    CD14(+) CD15(-) HLA-DR(-) myeloid-derived suppressor cells impair antimicrobial responses in patients with acute-on-chronic liver failure.
    Gut. 2018;67:1155-1167.
    PubMed     Text format     Abstract available


    May 2018
  69. GRETEN TF, Korangy F
    CDK20 inhibition and immune checkpoint blockade: bringing cancer biology and tumour immunology together to develop novel treatment options for HCC.
    Gut. 2018;67:783-784.
    PubMed     Text format    


  70. GAO B, Ma J, Xiang X
    MAIT cells: a novel therapeutic target for alcoholic liver disease?
    Gut. 2018;67:784-786.
    PubMed     Text format    


  71. RIVA A, Patel V, Kurioka A, Jeffery HC, et al
    Mucosa-associated invariant T cells link intestinal immunity with antibacterial immune defects in alcoholic liver disease.
    Gut. 2018;67:918-930.
    PubMed     Text format     Abstract available


  72. GRANDER C, Adolph TE, Wieser V, Lowe P, et al
    Recovery of ethanol-induced Akkermansia muciniphila depletion ameliorates alcoholic liver disease.
    Gut. 2018;67:891-901.
    PubMed     Text format     Abstract available


    April 2018
  73. SENNI N, Savall M, Cabrerizo Granados D, Alves-Guerra MC, et al
    beta-catenin-activated hepatocellular carcinomas are addicted to fatty acids.
    Gut. 2018 Apr 12. pii: gutjnl-2017-315448. doi: 10.1136/gutjnl-2017-315448.
    PubMed     Text format     Abstract available



  74. Correction: Discoidin domain receptor 2 deficiency predisposes hepatic tissue to colon carcinoma metastasis.
    Gut. 2018;67:782.
    PubMed     Text format    


    March 2018
  75. HIRSCHFIELD GM, Dyson JK, Alexander GJM, Chapman MH, et al
    The British Society of Gastroenterology/UK-PBC primary biliary cholangitis treatment and management guidelines.
    Gut. 2018 Mar 28. pii: gutjnl-2017-315259. doi: 10.1136/gutjnl-2017-315259.
    PubMed     Text format     Abstract available


  76. MAURER MH
    Diagnosis of hepatocellular carcinoma with MRI.
    Gut. 2018 Mar 16. pii: gutjnl-2018-315999. doi: 10.1136/gutjnl-2018-315999.
    PubMed     Text format    


  77. LIN HH, Tseng TC, Kao JH
    Large and middle hepatitis B surface antigen: the lower the better?
    Gut. 2018 Mar 7. pii: gutjnl-2018-316030. doi: 10.1136/gutjnl-2018-316030.
    PubMed     Text format    



  78. Correction: Gut roundtable meeting paper: selected recent advances in hepatocellular carcinoma.
    Gut. 2018;67:594.
    PubMed     Text format    


  79. LUETKENS JA, Klein S, Traeber F, Schmeel FC, et al
    Quantitative liver MRI including extracellular volume fraction for non-invasive quantification of liver fibrosis: a prospective proof-of-concept study.
    Gut. 2018;67:593-594.
    PubMed     Text format    


  80. HESSMANN E, Patzak MS, Klein L, Chen N, et al
    Fibroblast drug scavenging increases intratumoural gemcitabine accumulation in murine pancreas cancer.
    Gut. 2018;67:497-507.
    PubMed     Text format     Abstract available


  81. SAMSON A, Bentham MJ, Scott K, Nuovo G, et al
    Oncolytic reovirus as a combined antiviral and anti-tumour agent for the treatment of liver cancer.
    Gut. 2018;67:562-573.
    PubMed     Text format     Abstract available


    February 2018
  82. HEO MJ, Kim TH, You JS, Blaya D, et al
    Alcohol dysregulates miR-148a in hepatocytes through FoxO1, facilitating pyroptosis via TXNIP overexpression.
    Gut. 2018 Feb 23. pii: gutjnl-2017-315123. doi: 10.1136/gutjnl-2017-315123.
    PubMed     Text format     Abstract available


  83. CHEW V, Lee YH, Pan L, Nasir NJM, et al
    Immune activation underlies a sustained clinical response to Yttrium-90 radioembolisation in hepatocellular carcinoma.
    Gut. 2018 Feb 13. pii: gutjnl-2017-315485. doi: 10.1136/gutjnl-2017-315485.
    PubMed     Text format     Abstract available


  84. RENZULLI M, Biselli M, Brocchi S, Granito A, et al
    New hallmark of hepatocellular carcinoma, early hepatocellular carcinoma and high-grade dysplastic nodules on Gd-EOB-DTPA MRI in patients with cirrhosis: a new diagnostic algorithm.
    Gut. 2018 Feb 3. pii: gutjnl-2017-315384. doi: 10.1136/gutjnl-2017-315384.
    PubMed     Text format     Abstract available


  85. LEE JH, Suh JH, Choi SY, Kang HJ, et al
    Tonicity-responsive enhancer-binding protein promotes hepatocellular carcinogenesis, recurrence and metastasis.
    Gut. 2018 Feb 2. pii: gutjnl-2017-315348. doi: 10.1136/gutjnl-2017-315348.
    PubMed     Text format     Abstract available


  86. PUENGEL T, Tacke F
    Repair macrophages in acute liver failure.
    Gut. 2018;67:202-203.
    PubMed     Text format    


  87. EFERL R, Trauner M
    Chromosomal instability in HCC: a key function for checkpoint kinase 2.
    Gut. 2018;67:204-205.
    PubMed     Text format    


    January 2018
  88. PERUGORRIA MJ, Esparza-Baquer A, Oakley F, Labiano I, et al
    Non-parenchymal TREM-2 protects the liver from immune-mediated hepatocellular damage.
    Gut. 2018 Jan 27. pii: gutjnl-2017-314107. doi: 10.1136/gutjnl-2017-314107.
    PubMed     Text format     Abstract available


  89. IBRAHIM SH, Hirsova P, Gores GJ
    Non-alcoholic steatohepatitis pathogenesis: sublethal hepatocyte injury as a driver of liver inflammation.
    Gut. 2018 Jan 24. pii: gutjnl-2017-315691. doi: 10.1136/gutjnl-2017-315691.
    PubMed     Text format     Abstract available


  90. CHEN CJ
    Global elimination of viral hepatitis and hepatocellular carcinoma: opportunities and challenges.
    Gut. 2018 Jan 24. pii: gutjnl-2017-315407. doi: 10.1136/gutjnl-2017-315407.
    PubMed     Text format    


  91. BANTEL H, Canbay A
    Loss of KRAS control as consequence of downregulated microRNA-622 in hepatocellular carcinoma and its potential therapeutic implication.
    Gut. 2018 Jan 20. pii: gutjnl-2017-315630. doi: 10.1136/gutjnl-2017-315630.
    PubMed     Text format    


  92. YIGIT B, Boyle M, Ozler O, Erden N, et al
    Plasma cell-free DNA methylation: a liquid biomarker of hepatic fibrosis.
    Gut. 2018 Jan 20. pii: gutjnl-2017-315668. doi: 10.1136/gutjnl-2017-315668.
    PubMed     Text format    


  93. PERNES G, Lancaster GI, Murphy AJ
    Take me to the liver: adipose tissue macrophages coordinate hepatic neutrophil recruitment.
    Gut. 2018 Jan 3. pii: gutjnl-2017-315393. doi: 10.1136/gutjnl-2017-315393.
    PubMed     Text format    


  94. NEWSOME PN, Cramb R, Davison SM, Dillon JF, et al
    Guidelines on the management of abnormal liver blood tests.
    Gut. 2018;67:6-19.
    PubMed     Text format     Abstract available


  95. WIESER V, Adolph TE, Grander C, Grabherr F, et al
    Adipose type I interferon signalling protects against metabolic dysfunction.
    Gut. 2018;67:157-165.
    PubMed     Text format     Abstract available


    December 2017
  96. DIETRICH P, Koch A, Fritz V, Hartmann A, et al
    Wild type Kirsten rat sarcoma is a novel microRNA-622-regulated therapeutic target for hepatocellular carcinoma and contributes to sorafenib resistance.
    Gut. 2017 Dec 23. pii: gutjnl-2017-315402. doi: 10.1136/gutjnl-2017-315402.
    PubMed     Text format     Abstract available


  97. CUI CP, Wong CC, Kai AK, Ho DW, et al
    SENP1 promotes hypoxia-induced cancer stemness by HIF-1alpha deSUMOylation and SENP1/HIF-1alpha positive feedback loop.
    Gut. 2017;66:2149-2159.
    PubMed     Text format     Abstract available


  98. CONIGLIARO A, Tripodi M, Parola M
    SENP1 activity sustains cancer stem cell in hypoxic HCC.
    Gut. 2017;66:2051-2052.
    PubMed     Text format    


    November 2017
  99. GERBES A, Zoulim F, Tilg H, Dufour JF, et al
    Gut roundtable meeting paper: selected recent advances in hepatocellular carcinoma.
    Gut. 2017 Nov 17. pii: gutjnl-2017-315068. doi: 10.1136/gutjnl-2017-315068.
    PubMed     Text format     Abstract available


    October 2017
  100. MAZARD T, Boonsirikamchai P, Overman MJ, Asran MA, et al
    Comparison of early radiological predictors of outcome in patients with colorectal cancer with unresectable hepatic metastases treated with bevacizumab.
    Gut. 2017 Oct 30. pii: gutjnl-2017-313786. doi: 10.1136/gutjnl-2017-313786.
    PubMed     Text format     Abstract available


  101. BIJNEN M, Josefs T, Cuijpers I, Maalsen CJ, et al
    Adipose tissue macrophages induce hepatic neutrophil recruitment and macrophage accumulation in mice.
    Gut. 2017 Oct 26. pii: gutjnl-2016-313654. doi: 10.1136/gutjnl-2016-313654.
    PubMed     Text format     Abstract available


  102. KIM GA, Lim YS, Han S, Choi J, et al
    High risk of hepatocellular carcinoma and death in patients with immune-tolerant-phase chronic hepatitis B.
    Gut. 2017 Oct 21. pii: gutjnl-2017-314904. doi: 10.1136/gutjnl-2017-314904.
    PubMed     Text format     Abstract available


  103. BROWN PM, Rotman Y
    What if Prometheus had steatosis? Potential use of FGF19 to promote regeneration of the fatty liver.
    Gut. 2017;66:1732-1733.
    PubMed     Text format    


    September 2017
  104. LV Y, Qi X, He C, Wang Z, et al
    Covered TIPS versus endoscopic band ligation plus propranolol for the prevention of variceal rebleeding in cirrhotic patients with portal vein thrombosis: a randomised controlled trial.
    Gut. 2017 Sep 28. pii: gutjnl-2017-314634. doi: 10.1136/gutjnl-2017-314634.
    PubMed     Text format     Abstract available


  105. ZHOU J, Liu M, Sun H, Feng Y, et al
    Hepatoma-intrinsic CCRK inhibition diminishes myeloid-derived suppressor cell immunosuppression and enhances immune-checkpoint blockade efficacy.
    Gut. 2017 Sep 22. pii: gutjnl-2017-314032. doi: 10.1136/gutjnl-2017-314032.
    PubMed     Text format     Abstract available


  106. MUELLER C, Waldburger N, Stampfl U, Kauczor HU, et al
    Non-invasive diagnosis of hepatocellular carcinoma revisited.
    Gut. 2017 Sep 12. pii: gutjnl-2017-314981. doi: 10.1136/gutjnl-2017-314981.
    PubMed     Text format    


  107. KIM W, Khan SK, Liu Y, Xu R, et al
    Hepatic Hippo signaling inhibits protumoural microenvironment to suppress hepatocellular carcinoma.
    Gut. 2017 Sep 2. pii: gutjnl-2017-314061. doi: 10.1136/gutjnl-2017-314061.
    PubMed     Text format     Abstract available



  108. Erratum: The rs2296651 (S267F) variant on NTCP (SLC10A1) is inversely associated with chronic hepatitis B and progression to cirrhosis and hepatocellular carcinoma in patients with chronic hepatitis B.
    Gut. 2017;66:1730.
    PubMed     Text format    


  109. BEDOSSA P, Tordjman J, Aron-Wisnewsky J, Poitou C, et al
    Systematic review of bariatric surgery liver biopsies clarifies the natural history of liver disease in patients with severe obesity.
    Gut. 2017;66:1688-1696.
    PubMed     Text format     Abstract available


  110. MAGDALENO F, Trebicka J
    Selective LOXL2 inhibition: potent antifibrotic effects in ongoing fibrosis and fibrosis regression.
    Gut. 2017;66:1540-1541.
    PubMed     Text format    


    August 2017
  111. PIANO S, Bartoletti M, Tonon M, Baldassarre M, et al
    Assessment of Sepsis-3 criteria and quick SOFA in patients with cirrhosis and bacterial infections.
    Gut. 2017 Aug 31. pii: gutjnl-2017-314324. doi: 10.1136/gutjnl-2017-314324.
    PubMed     Text format     Abstract available


  112. JIAO N, Baker SS, Chapa-Rodriguez A, Liu W, et al
    Suppressed hepatic bile acid signalling despite elevated production of primary and secondary bile acids in NAFLD.
    Gut. 2017 Aug 3. pii: gutjnl-2017-314307. doi: 10.1136/gutjnl-2017-314307.
    PubMed     Text format     Abstract available


  113. HO DWH, Chan LK, Chiu YT, Xu IMJ, et al
    TSC1/2 mutations define a molecular subset of HCC with aggressive behaviour and treatment implication.
    Gut. 2017;66:1496-1506.
    PubMed     Text format     Abstract available


  114. BERASAIN C, Lechel A
    Targeting the correct target in HCC.
    Gut. 2017;66:1352-1354.
    PubMed     Text format    


    July 2017
  115. XIANG DM, Sun W, Ning BF, Zhou TF, et al
    The HLF/IL-6/STAT3 feedforward circuit drives hepatic stellate cell activation to promote liver fibrosis.
    Gut. 2017 Jul 28. pii: gutjnl-2016-313392. doi: 10.1136/gutjnl-2016-313392.
    PubMed     Text format     Abstract available


  116. CORRAL JE, Mousa OY, Riegert-Johnson DL
    Massive gastrointestinal bleeding after transjugular intrahepatic portosystemic shunt (TIPS).
    Gut. 2017 Jul 7. pii: gutjnl-2017-314254. doi: 10.1136/gutjnl-2017-314254.
    PubMed     Text format    


  117. ALBANO E, Stickel F
    Targeting toll-like receptor 7/8 improves host anti-infective response in alcoholic cirrhosis.
    Gut. 2017 Jul 7. pii: gutjnl-2017-314437. doi: 10.1136/gutjnl-2017-314437.
    PubMed     Text format    


  118. HARDY T, Zeybel M, Day CP, Dipper C, et al
    Plasma DNA methylation: a potential biomarker for stratification of liver fibrosis in non-alcoholic fatty liver disease.
    Gut. 2017;66:1321-1328.
    PubMed     Text format     Abstract available


  119. CALVISI D, Eferl R
    CDK4/6 inhibition and sorafenib: a menage a deux in HCC therapy?
    Gut. 2017;66:1179-1180.
    PubMed     Text format    


  120. MANDORFER M, Peck-Radosavljevic M, Reiberger T
    Prevention of progression from small to large varices: are we there yet? An updated meta-analysis.
    Gut. 2017;66:1347-1349.
    PubMed     Text format    


    June 2017
  121. ROLAS L, Boussif A, Weiss E, Letteron P, et al
    NADPH oxidase depletion in neutrophils from patients with cirrhosis and restoration via toll-like receptor 7/8 activation.
    Gut. 2017 Jun 10. pii: gutjnl-2016-313443. doi: 10.1136/gutjnl-2016-313443.
    PubMed     Text format     Abstract available


  122. JIANG RY, Yang L
    The role of hepatokines in NAFLD-related extrahepatic diseases: culprit or accomplice?
    Gut. 2017 Jun 10. pii: gutjnl-2017-314411. doi: 10.1136/gutjnl-2017-314411.
    PubMed     Text format    


  123. LYU N, Lin Y, Kong Y, Zhang Z, et al
    FOXAI: a phase II trial evaluating the efficacy and safety of hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin for advanced hepatocellular carcinoma.
    Gut. 2017 Jun 7. pii: gutjnl-2017-314138. doi: 10.1136/gutjnl-2017-314138.
    PubMed     Text format    


  124. WANG Z, Zhang H, Han J, Wu MC, et al
    High body mass index and the risk of hepatocellular carcinoma.
    Gut. 2017 Jun 7. pii: gutjnl-2017-314259. doi: 10.1136/gutjnl-2017-314259.
    PubMed     Text format    


  125. BAJAJ JS, Liu EJ, Kheradman R, Fagan A, et al
    Fungal dysbiosis in cirrhosis.
    Gut. 2017 Jun 3. pii: gutjnl-2016-313170. doi: 10.1136/gutjnl-2016-313170.
    PubMed     Text format     Abstract available


  126. KULLAK-UBLICK GA, Andrade RJ, Merz M, End P, et al
    Drug-induced liver injury: recent advances in diagnosis and risk assessment.
    Gut. 2017;66:1154-1164.
    PubMed     Text format     Abstract available


  127. ADAMS LA, Anstee QM, Tilg H, Targher G, et al
    Non-alcoholic fatty liver disease and its relationship with cardiovascular disease and other extrahepatic diseases.
    Gut. 2017;66:1138-1153.
    PubMed     Text format     Abstract available


  128. BROOKS AJ, Smith PJ, Cohen R, Collins P, et al
    UK guideline on transition of adolescent and young persons with chronic digestive diseases from paediatric to adult care.
    Gut. 2017;66:988-1000.
    PubMed     Text format     Abstract available


    May 2017
  129. PANKOWICZ FP, Jarrett KE, Lagor WR, Bissig KD, et al
    CRISPR/Cas9: at the cutting edge of hepatology.
    Gut. 2017 May 9. pii: gutjnl-2016-313565. doi: 10.1136/gutjnl-2016-313565.
    PubMed     Text format     Abstract available


  130. THOMAS E
    Hepatitis B virus X protein: TRIMming antiviral defences in hepatocytes.
    Gut. 2017 May 5. pii: gutjnl-2017-314013. doi: 10.1136/gutjnl-2017-314013.
    PubMed     Text format    


  131. BREITKOPF-HEINLEIN K, Meyer C, Konig C, Gaitantzi H, et al
    BMP-9 interferes with liver regeneration and promotes liver fibrosis.
    Gut. 2017;66:939-954.
    PubMed     Text format     Abstract available


    April 2017
  132. TRIANTAFYLLOU E, Pop OT, Possamai LA, Wilhelm A, et al
    MerTK expressing hepatic macrophages promote the resolution of inflammation in acute liver failure.
    Gut. 2017 Apr 27. pii: gutjnl-2016-313615. doi: 10.1136/gutjnl-2016-313615.
    PubMed     Text format     Abstract available


  133. ALLWEISS L, Volz T, Giersch K, Kah J, et al
    Proliferation of primary human hepatocytes and prevention of hepatitis B virus reinfection efficiently deplete nuclear cccDNA in vivo.
    Gut. 2017 Apr 20. pii: gutjnl-2016-312162. doi: 10.1136/gutjnl-2016-312162.
    PubMed     Text format     Abstract available


  134. HANIN G, Yayon N, Tzur Y, Haviv R, et al
    miRNA-132 induces hepatic steatosis and hyperlipidaemia by synergistic multitarget suppression.
    Gut. 2017 Apr 5. pii: gutjnl-2016-312869. doi: 10.1136/gutjnl-2016-312869.
    PubMed     Text format     Abstract available


  135. LI M, He Y, Zhou Z, Ramirez T, et al
    MicroRNA-223 ameliorates alcoholic liver injury by inhibiting the IL-6-p47phox-oxidative stress pathway in neutrophils.
    Gut. 2017;66:705-715.
    PubMed     Text format     Abstract available


  136. HUR K, Toiyama Y, Okugawa Y, Ide S, et al
    Circulating microRNA-203 predicts prognosis and metastasis in human colorectal cancer.
    Gut. 2017;66:654-665.
    PubMed     Text format     Abstract available


  137. WANG S, Ding WX
    A small RNA in neutrophils protects against acute-on-chronic alcoholic liver injury.
    Gut. 2017;66:565-566.
    PubMed     Text format    


    March 2017
  138. CARLONI V, Lulli M, Madiai S, Mello T, et al
    CHK2 overexpression and mislocalisation within mitotic structures enhances chromosomal instability and hepatocellular carcinoma progression.
    Gut. 2017 Mar 30. pii: gutjnl-2016-313114. doi: 10.1136/gutjnl-2016-313114.
    PubMed     Text format     Abstract available


  139. HAGSTROM H, Tynelius P, Rasmussen F
    High BMI in late adolescence predicts future severe liver disease and hepatocellular carcinoma: a national, population-based cohort study in 1.2 million men.
    Gut. 2017 Mar 20. pii: gutjnl-2016-313622. doi: 10.1136/gutjnl-2016-313622.
    PubMed     Text format     Abstract available


  140. PARSEUS A, Sommer N, Sommer F, Caesar R, et al
    Microbiota-induced obesity requires farnesoid X receptor.
    Gut. 2017;66:429-437.
    PubMed     Text format     Abstract available


    February 2017
  141. SINN DH, Kang D, Chang Y, Ryu S, et al
    Non-alcoholic fatty liver disease and progression of coronary artery calcium score: a retrospective cohort study.
    Gut. 2017;66:323-329.
    PubMed     Text format     Abstract available


  142. TARGHER G
    Non-alcoholic fatty liver disease as driving force in coronary heart disease?
    Gut. 2017;66:213-214.
    PubMed     Text format    


    January 2017
  143. ROTMAN Y, Sanyal AJ
    Current and upcoming pharmacotherapy for non-alcoholic fatty liver disease.
    Gut. 2017;66:180-190.
    PubMed     Text format     Abstract available


  144. LI X, Yao W, Yuan Y, Chen P, et al
    Targeting of tumour-infiltrating macrophages via CCL2/CCR2 signalling as a therapeutic strategy against hepatocellular carcinoma.
    Gut. 2017;66:157-167.
    PubMed     Text format     Abstract available


  145. AUGUSTIN S, Pons M, Genesca J
    Ruling in and ruling out with elastography in compensated advanced chronic liver disease.
    Gut. 2017;66:197-198.
    PubMed     Text format    


    September 2016
  146. SINGH A, Smith PJ, Cropley IM, Planche KL, et al
    Gallstone mimicry: a rare cause of abdominal pain.
    Gut. 2016 Sep 29. pii: gutjnl-2016-312706. doi: 10.1136/gutjnl-2016-312706.
    PubMed     Text format    


    July 2016
  147. GRILLET F, Bayet E, Villeronce O, Zappia L, et al
    Circulating tumour cells from patients with colorectal cancer have cancer stem cell hallmarks in ex vivo culture.
    Gut. 2016 Jul 25. pii: gutjnl-2016-311447. doi: 10.1136/gutjnl-2016-311447.
    PubMed     Text format     Abstract available


    March 2016
  148. GRIESMANN H, Drexel C, Milosevic N, Sipos B, et al
    Pharmacological macrophage inhibition decreases metastasis formation in a genetic model of pancreatic cancer.
    Gut. 2016 Mar 24. pii: gutjnl-2015-310049. doi: 10.1136/gutjnl-2015-310049.
    PubMed     Text format     Abstract available


    February 2016
  149. EHLKEN H, Wroblewski R, Corpechot C, Arrive L, et al
    Spleen size for the prediction of clinical outcome in patients with primary sclerosing cholangitis.
    Gut. 2016 Feb 26. pii: gutjnl-2016-311452. doi: 10.1136/gutjnl-2016-311452.
    PubMed     Text format    


  150. COLOMBEL JF, Sands BE, Rutgeerts P, Sandborn W, et al
    The safety of vedolizumab for ulcerative colitis and Crohn's disease.
    Gut. 2016 Feb 18. pii: gutjnl-2015-311079. doi: 10.1136/gutjnl-2015-311079.
    PubMed     Text format     Abstract available


    September 2015
  151. KLEIN S, Rick J, Lehmann J, Schierwagen R, et al
    Janus-kinase-2 relates directly to portal hypertension and to complications in rodent and human cirrhosis.
    Gut. 2015 Sep 17. pii: gutjnl-2015-309600. doi: 10.1136/gutjnl-2015-309600.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Liver Diseases is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: